Livanova PLC Stock News

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles.

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldm...

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.

LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial...

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its Board of Directors has appointed Susan Podlogar to the Board, effective October 8, 2024.

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024.